Abstract
The importance of ascertaining the possible presence of unstable metabolites at an early stage in the drug development process cannot be underestimated. Failure to detect labile metabolites could lead to costly delays to development. Very often, erratic or difficult to explain analytical or kinetic data provide clues to metabolite degradation, the most commonly encountered reaction being the conversion of a metabolite to parent drug. Examples of unstable glucuronide conjugates, N-oxides, alcohols and phenols abound in the literature. They are not easy to find, however, and have to be ‘mined’ by extensive searching. This report, by no means exhaustive, brings together the major examples according to substance class. Remedial action to avoid metabolite degradation is discussed, as well as a number of specific examples which cannot be categorised under the main substance classes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gorrod JW (1978) Pitfalls in drug metabolism methodology. In: Gorrod JW and Beckett AH (ed) Drug Metabolism in Man. Taylor and Francis Ltd., London
Curry SH (1976) J Pharm Pharmac 28:467–468
Debrauwer L, Zalko D, Bories G, Tulliez J (1997) Rapid Comm in Mass Spec 11:1089–1094
Lenz EM, Greatbanks D, Wilson ID, Spraul M, Hofmann M, Troke J, Lindon JC, Nicholson JK (1996) Anal Chem 68:2832–2837
Jemnitz K, Levai F, Monostroy K, Szatmari I, Vereczkey L (2000) Eur J Drug Met and Pharmac 25:153–160
Kowalczyk I, Hawes EM, McKay G (2000) J Pharm and Biomed Anal 22:803–811
Hawes EM (1998) Drug Met and Disp 26:830–837
Chiu SHl, Huskey SEW (1998) Drug Met and Disp 26:838–847
McIntyre IM, Norman TR, Burrows GD (1981) Clin Chem 1:203–204
Thorré K, Pravda M, Sarre S, Ebinger E, Michotte Y (1997) J Chrom B 694:297–303
Coutts RT, Baker GB, Daneshtalab M (1993) J Chromatog B 615:265–272
Sagfren SL, Reid JM, Rios R, Ames MA (2001) J Chromatog B 754:91–96
Fan PW, Zhang F, Bolton JL (2000) Chem Res Toxicol 13:45–52
Timm U, Saner A (1986) J Chromatogr A 378:25–34
Bonnefous J-L, Boulieu R, Lahet C (1992) J Pharm Sci 81:341–344
Momerency G, Van Cauwenberghe KThJ, Slee PH, Van Oosterom AT, De Bruijn EA (1994) Biolog Mass Spectrom 23:149–158
Joqueviel C, Gilard V, Martino R, Malet-Martino M, Niemeyer U (1997) Cancer Chemother Pharmacol 40:391–399
Van Maanen MJ, Doesburg Smits K, Damen JMA, Heck AJR, Beijnen JH (2000) Int J Pharmaceut 200:187–194
Wyss R, Bucheli F (1992) J Chromatogr 593:55–62
Wyss R (1995) J Chromatogr B 671:381–425
Wyss R, Bucheli F (1997) J Chromatogr B 700:31–47
Chou RC, Wyss R, Huselton CA, Wiegand U-W (1992) Xenobiotica 22:993–1002
Schmitt-Hoffmann AH, Dittrich S, Saulnier E, Schenk P, Chou RC (1995) Life Sciences 57:407–412
Tjornelund J, Hansen ST (1991) J Chromatogr B 570:224–228
Hijazi Y, Bolon M, Boulieu R (2001) Clin Chem 47:1713–1715
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented at: 15th International Bioanalytical Forum. The Changing Role of Bioanalysis: Discovery to Market, Guildford, UK, July 1–4, 2003
Rights and permissions
About this article
Cite this article
Dell, D. Labile Metabolites. Chromatographia 59 (Suppl 2), S139–S148 (2004). https://doi.org/10.1365/s10337-003-0169-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1365/s10337-003-0169-5